Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
IRVINE, Calif. - Edwards Lifesciences (NYSE:EW) reported third-quarter earnings that exceeded analyst expectations, driven by strong performance across all product groups. The company raised its full-year guidance following the better-than-expected results.
Edwards’ shares edged up 0.10% following the announcement as investors responded positively to the results and improved outlook.
The heart valve maker posted adjusted earnings per share of $0.67 for the quarter ended September 30, 2025, surpassing the analyst consensus of $0.59. Revenue came in at $1.55 billion, above the $1.5 billion consensus estimate and representing a 14.7% increase from the same period last year, or 12.6% on an adjusted basis.
The company’s Transcatheter Aortic Valve Replacement (TAVR) business, its largest segment, generated sales of $1.15 billion, up 12.4% year-over-year or 10.6% on a constant currency basis. Transcatheter Mitral and Tricuspid Therapies (TMTT) saw impressive growth with sales reaching $145.2 million, a 59.3% increase YoY.
"Our strong results represent another quarter of double-digit sales growth, driven by our comprehensive portfolio across multiple therapeutic areas," said Bernard Zovighian, CEO of Edwards Lifesciences. "Based on our better-than-expected performance, reflecting the patient-focused contributions of our talented employees, we are raising our 2025 sales and EPS guidance."
Edwards increased its full-year 2025 adjusted earnings per share guidance to $2.56-$2.62, up from its previous outlook of $2.45-$2.55 and above the analyst consensus of $2.51. The company also raised its total sales growth guidance to the high end of 9-10% and increased its TAVR sales growth forecast to 7-8% from 6-7% previously.
The updated outlook reflects continued momentum in the company’s structural heart portfolio and expanding global presence. Edwards maintained its guidance for the TMTT and Surgical product groups.
For the fourth quarter, Edwards projects total sales between $1.51 billion and $1.59 billion with adjusted EPS of $0.58 to $0.64.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.